Antifungal activity of miltefosine against both azole-susceptible and -resistant Aspergillus strains.

Autor: Haghani I; Invasive Fungi Research Centre, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran., Yahyazadeh Z; Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran., Hedayati MT; Invasive Fungi Research Centre, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran; Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran., Shokohi T; Invasive Fungi Research Centre, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran; Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran., Badali H; Invasive Fungi Research Centre, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran; Department of Molecular Microbiology & Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, Texas, USA., Khojasteh S; Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran., Akhtari J; Department of Nano-biomedicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran., Javidnia J; Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran., Moazeni M; Invasive Fungi Research Centre, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran; Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran., Al-Harrasi A; Natural and Medical Sciences Research Centre, University of Nizwa, Nizwa, Oman., Aghili SR; Invasive Fungi Research Centre, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran; Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran., Kermani F; Invasive Fungi Research Centre, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran; Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran., Hajheydari Z; Invasive Fungi Research Centre, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran; Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran., Al Hatmi AMS; Natural and Medical Sciences Research Centre, University of Nizwa, Nizwa, Oman; Centre of Expertise in Mycology, Radboud University Medical Centre/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. Electronic address: a.alhatmi@unizwa.edu.om., Abastabar M; Invasive Fungi Research Centre, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran; Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran. Electronic address: mabastabar@gmail.com.
Jazyk: angličtina
Zdroj: International journal of antimicrobial agents [Int J Antimicrob Agents] 2023 Mar; Vol. 61 (3), pp. 106715. Date of Electronic Publication: 2023 Jan 12.
DOI: 10.1016/j.ijantimicag.2023.106715
Abstrakt: Miltefosine, an alkylphosphocholine, has been approved recently for the treatment of visceral leishmaniasis. Miltefosine has shown promise as a treatment for paracoccidioidomycosis, and has mixed activity against other fungi and yeast. There are limited data on the in-vitro activity of miltefosine against azole-resistant and -susceptible Aspergillus spp. As such, the aim of this study was to determine the in-vitro activity of miltefosine against Aspergillus strains. Miltefosine was tested against 108 azole-susceptible and -resistant Aspergillus strains isolated from Iran and other countries using the broth microdilution method. Miltefosine was found to be effective against azole-resistant Aspergillus isolates, with minimum inhibitory concentrations (MICs) ranging from 1.562 to 6.25 µg/mL. MIC 50 and MIC 90 were 1.562 and 3.125 µg/mL, respectively. Miltefosine had a higher geometric mean MIC (2.459 µg/mL) for wild-type Aspergillus isolates than itraconazole (0.220 µg/mL) and voriconazole (0.298 µg/mL). No significant difference was found between miltefosine MICs for azole-resistant Aspergillus isolates and azole-susceptible Aspergillus isolates (P>0.05). Miltefosine appears to have good in-vitro activity against azole-resistant Aspergillus strains, according to these findings. Furthermore, the findings suggest that miltefosine could be used to treat infections caused by azole-resistant Aspergillus spp.
Competing Interests: Competing interests None declared.
(Copyright © 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: